Surgeons lean on Zimmer Biomet’s Coonrad/ Morrey elbow for complex revisions

Zimmer Biomet’s Coonrad/Morrey Total Elbow System remains a go-to implant for complex elbow arthritis and revision cases, offering modular components, cemented fixation and long clinical use that still anchors the company’s extremities portfolio.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 12:26 PM ET. Details in the imprint.

Zimmer Biomet’s Coonrad/Morrey Total Elbow System sits in a small but demanding corner of joint replacement: end-stage elbow arthritis, post-traumatic deformity and complex revision surgery where pain relief and predictable motion matter more than speed of recovery. The long-running implant line offers a semi-constrained, linked hinge design with cemented humeral and ulnar components, and remains one of the most widely used total elbow replacement systems globally in specialized upper-extremity centers. Zimmer Biomet characterizes the Coonrad/Morrey platform as a leading total elbow solution with decades of clinical experience.

How the Coonrad/Morrey Total Elbow System is put to work in the OR

Technically, the Coonrad/Morrey Total Elbow System is a linked, semi-constrained prosthesis, meaning the humeral and ulnar components are mechanically connected through a hinge but allow a small degree of varus-valgus and rotational play to reduce stress on the bone-cement interface. The implant family covers primary and revision procedures through multiple stem lengths, offset options and interchangeable bushings and pins, so surgeons can tailor stability and range of motion to the individual anatomy and bone stock. The system is intended for patients with painful rheumatoid arthritis, post-traumatic arthritis, irreparable distal humerus fractures and for salvage of failed previous elbow surgeries where arthrodesis would severely limit function.

Implantation follows a standard posterior approach with triceps-sparing or triceps-on techniques depending on surgeon preference, and both the humeral and ulnar canals are typically prepared for cemented fixation to secure stability in often osteopenic bone. The hinge mechanism is assembled intraoperatively, and surgeons can choose between different bearing and linkage options to balance constraint against the risk of loosening, particularly in younger or more active patients. Postoperatively, patients usually start controlled range-of-motion exercises early under the protection of activity restrictions to preserve implant longevity, as heavy lifting can accelerate wear and loosening.

Because total elbow arthroplasty volumes are a fraction of hip and knee replacements, a system like Coonrad/Morrey occupies an outsized role in training and reference cases. Fellowship programs in hand and upper-extremity surgery routinely cite it as a baseline design when discussing semi-constrained elbows, and published series over many years have reported meaningful pain relief and functional gains in carefully selected patients, albeit with higher complication and revision rates than seen in larger joints. This makes straightforward instrumentation and predictable kinematics crucial; surgeons often emphasize that having a familiar, modular system on the shelf can be the difference between converting a difficult distal humerus fracture to a stable replacement or facing prolonged reconstruction attempts with uncertain outcomes.

The Coonrad/Morrey family also helps anchor Zimmer Biomet’s broader elbow and extremities portfolio, which spans trauma plating, radial head prostheses and soft-tissue reconstruction tools that often interface with or precede a total elbow. Strategically, maintaining a mature but clinically entrenched system gives the company a defensible position in a niche market where surgeon loyalty and institutional familiarity weigh heavily in implant choice. According to recent coverage of Zimmer Biomet’s performance, extremities, trauma and sports medicine collectively contribute a meaningful share of revenue growth alongside the large-joint knee and hip franchises, underscoring the commercial relevance of specialty implants such as Coonrad/Morrey within the overall business mix. A June 2026 analysis of Zimmer Biomet highlights solid net sales growth driven in part by extremities and trauma products.

Zimmer Biomet trades on the New York Stock Exchange under the ticker ZBH, and its shares, tied to ISIN US98956P1021, changed hands at around $118 in mid-June 2026 on the back of steady large-joint demand and ongoing portfolio optimization. NYSE data show the company’s US listing as the primary venue for Zimmer Biomet shares.

Coonrad/Morrey Total Elbow System in brief

• Product: Coonrad/Morrey Total Elbow System
• Manufacturer: Zimmer Biomet Holdings Inc.
• Category: New Release/Launch (extremities implant)
• Launch date: Longstanding system with decades of clinical use; specific initial launch year not stated
• MSRP / Price: Not publicly disclosed; contract-based hospital pricing
• Availability: Distributed to hospitals and surgical centers via Zimmer Biomet’s orthopedic sales channels in North America and international markets
• Target audience: Orthopedic and upper-extremity surgeons treating advanced elbow arthritis, complex fractures and revision cases
• Key differentiator / USP: Semi-constrained, linked design with cemented fixation and modular stems widely used in complex elbow arthroplasty

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.